Home / Leaderboard / Roivant Sciences Ltd.
Roivant Sciences Ltd.
Matt Gline · Asset Manager · Venture
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company founded in 2014 by Vivek Ramaswamy that focuses on accelerating the development and commercialization of innovative medicines. The company utilizes a unique hub-and-spoke model, creating specialized subsidiary companies known as Vants to develop specific drug candidates and healthcare technologies. Roivant identifies and acquires deprioritized assets from major pharmaceutical companies, leveraging its proprietary computational platform and centralized resources to advance these therapies through clinical trials. This approach allows the organization to diversify risk while maintaining operational focus across various therapeutic areas, including immunology, dermatology, and oncology. Since its inception, Roivant has successfully launched several public Vants and maintains a significant portfolio of clinical-stage programs.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +132.5% |
| YTD return | +52.1% |
| Sharpe ratio | 4.41 |
| Win rate | 100% |
| AUM | $0.0B |
| Inception | Oct 1, 2025 |
| Updated | Sep 3, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.0B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://roivant.com |
Current Holdings
Updated on Sep 3, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| IMVT | Immunovant Inc | 97.0% | +139.4% |
| ABUS | Arbutus Biopharma Corp | 3.0% | +11.5% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Oct 1, 2025 | BUY | ABUS | 0.0% → 5.4% |
| Oct 1, 2025 | BUY | IMVT | 0.0% → 94.6% |
Investment Style Analysis
Roivant Sciences Ltd. is widely recognized for employing a Venture strategy. As of Sep 3, 2026, the firm oversees approximately $0.0B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Oct 1, Roivant Sciences Ltd. made a significant move by increasing exposure to ABUS. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Roivant Sciences operates on a philosophy of systematic drug development through the acquisition of high-potential, under-valued pharmaceutical assets. By deploying a decentralized Vant model, the institution provides dedicated leadership and focused capital to individual programs, effectively acting as an incubator and manager for a diverse pipeline of biotechnology companies. Their strategy integrates advanced data analytics with a lean operational structure to reduce the time and cost of bringing new therapies to market, emphasizing the revitalization of clinical-stage candidates that have been deprioritized by larger industry incumbents.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Roivant Sciences Ltd..
Similar Investment Style
Based on Venture.
- Accel Partners — Jim Swartz · 3M +20.6%
- Deer Management Co. LLC — Robert P. Goodman · 3M +17.9%
- Nextech Invest Ltd. — Alfred Scheidegger · 3M +33.0%
- Sofinnova Investment, Inc. — James Healy · 3M +15.7%
Frequently asked questions
How is the simulated portfolio for Roivant Sciences Ltd. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Roivant Sciences Ltd.'s largest holding?
As of the latest filing, Roivant Sciences Ltd.'s top position is Immunovant Inc (IMVT), representing 97.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Roivant Sciences Ltd.'s historical performance and risk profile?
Our simulation indicates a total return of +132.5% with a win rate of 100%. Notably, the portfolio maintains a Sharpe Ratio of 4.41, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Roivant Sciences Ltd. primarily invest in?
Roivant Sciences Ltd. has a strong preference for the Biotechnology sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Roivant Sciences Ltd.'s portfolio concentrated or diversified?
Roivant Sciences Ltd. runs a highly concentrated portfolio with 2 disclosed positions. The top 3 holdings alone account for 100.0% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Roivant Sciences Ltd. performed in 2026?
Our AI-simulated model portfolio for Roivant Sciences Ltd. tracks a Year-to-Date (YTD) return of +52.1%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Matt Gline manage Roivant Sciences Ltd. directly?
Yes, Matt Gline serves as the key portfolio manager for Roivant Sciences Ltd., overseeing the investment strategy and final capital allocation decisions.